Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

Two years after Neil Armstrong walked on the Moon, US president Richard Nixon declared a new frontier in American scientific ...

Special measures for the Work-Sharing Program in response to the threat or potential realization of U.S. tariffs are in effect from March 7, 2025 until March 6, 2026. Further details regarding the ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

“Pharmac operates independently, but it must work within the budget constraints set by the government,” Mr Seymour says.

"Pharmac operates independently, but it must work within the budget constraints set by the government," Mr Seymour says. "Today represents another step forward for cancer patients as the $604 million ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.